Can absolute oral bioavailability in humans be predicted from animals? A comparison of allometry and different indirect methods

Drug Metabolism and Drug Interactions

Volumn 16, Issue 2, 2000, Pages 143-155

  Mahmood, Iftekhar ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Absolute bioavailability; Allometric scaling; Clearance; Liver blood flow

Indexed keywords

ACCURACY; ALLOMETRY; ANALYTIC METHOD; ANIMAL MODEL; ARTICLE; CALCULATION; DRUG BIOAVAILABILITY; HUMAN; LIVER BLOOD FLOW; NONHUMAN; PREDICTION; SPECIES DIFFERENCE;

EID: 0033910845     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2000.16.2.143     Document Type: Article

References (28)

1. Sacher G. Relation of lifespan to brain weight and body weight in mammals. In. Wolstenholme GEW, O'Connor M, eds. CIBA Foundation Colloquia on Aging. London; Churchill, 1959; 115-133.
2. Mahmood I, Balian JD. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26: 887-895.
3. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc., 1982.
4. Obach RS, Baxter JG, Liston TE, Silber BM, Jones C, Macintyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. J Pharmacol Exp Ther 1997; 283: 46-58.
5. Cook CS, Rozek LF, StoIzenbach J, Anderson S, Schoenhard GL, Karim A. Pharmacokinetics of a novel antiarrhythmic drug, actisomide. Pharm Res 1993; 10: 427-433.
6. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ, The metabolism and Pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1998; 12 (Suppl): S55-S59.
7. Kaye B, Brearley CJ, Cussans NJ, Herron M, Humphrey MJ, Mollat AR. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica 1997; 27: 1091-1102.
8. Feng MR, Loo J, Wright J. Disposition of the antipsychotic agent C-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Drug Metab Disp 1998; 26: 982-988.
9. Smith DA, Rasmussen HS, Stopher DA, Walker, DK. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 1992; 22: 709-719.
10. Tuerck D, Wolfinger H. Animal pharmacokinetics of fradafiban, a potent fibrinogen receptor (GPIIh/IIa) antagonist after oral administration of its double prodrug lefradafiban. Pharm Res 1998; 1: S-674.
11. Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C, Roth W. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Disp 1998; 26: 576-584.
12. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. Meloxicam: Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Disp 1995; 23: 1206-1213.
13. Rane A, Hogstedt S, Lindberg B, Regardh CG, Jorulf H. Comparison of different clearance estimates for metoprolol in the Rhesus monkey. J Pharmacol Exp Ther 1984; 228: 774-778.
14. Belpaire FM, Smet FD, Vynckier LJ, Vermeulen AM, Rosseel MT, Bogaert MG, Moachon-Chauvelot, L. Effect of aging on the pharmacokinetics of metoprolol and propranolol in the rat. J Pharmacol Exp Ther 1990; 254: 116-122.
15. Murthy SS, Nelson WL, Shen DD, Power JM, Cahill CM, MClean AJ. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereo-chemical aspects. Drug Metab Disp 1991; 19: 1093-1100.
16. Bortolotti A, Castelli D, Verotta D, Bonati M. Pharmacokinetic and pharmacodynamic modeling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokin 1989; 14: 145-151.
17. Miline RW, Nation RL, Somogyi AA. The disposition of morphine and its 3-and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996; 28: 345-472.
18. Shiobara Y, Higuchi S. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasolidator, in various species. Xenobiotica 1980; 6: 447-454.
19. Scatina JA, Kimmel HB, Weinstein V, Troy SM, Sisenwine SF, Cayen MN. Species differences in the pharmacokinetics of recamam, a new anti-arrhythmic drug. Biopharm Drug Disp 1990; 11; 445-461.
20. Coassolo P, Fischli W, Clozel J-P, Chou C. Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. Xenobiotica 1996; 26: 333-345.
21. Kleinbloesem CH, Weber C., Fahmer E., Dellenbach M, Welker H, Schroter V, Beltz GG. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Therap 1993; 8: 585-592.
22. Walker DK, Ackland, MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310.
23. Riekosezewski W, Chow FS, Jusko WJ. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. Drug Metab Disp 1993; 21: 690-698.
24. Takada K, Usuda H, Oh-hashi, M, Yoshikawa H. Muranishi S, Tanaka H. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administration to rats. J Pharmacobio-dyn 1991; 14: 34-42.
25. Venkataramanan R, Cadoff JE, Warty V, Iwasaki K, Nagase K, Krajack A, Imventarza O, Todo S, Fung J, Starzl TE. Pharmacokinetics of FK-506: Preclinical and clinical studies. Transplant Proc 1990; 22 (Suppl 1): 52-56.
26. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, Mcmichael J, Lever J, Burckhart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430.
27. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach, J Pharmacol Exp Ther 1996; 277: 1630-1641.
28. Komp JR, Olson SC, Graham R. Bayesian estimation of troglitazone pharmacokinetic parameters following intravenous and oral administration. Pharm Res 1997; 14 (Suppl): S-243.